February 20, 2018 07:53 AM EST

Aimmune's PhIII peanut allergy study wows on the primary endpoint, setting up FDA pitch -- and shares slide

John Carroll

Editor & Founder

Four months after DBV Technologies stock was crushed by a shaky set of pivotal data for its peanut allergy drug, rival Aimmune Therapeutics $AIMT says …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Aimmune's PhIII peanut allergy study wows on the primary endpoint, setting up FDA pitch -- and shares slide

John Carroll

Editor & Founder

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

Biopharma begins to contemplate an RFK Jr.-influenced FDA if Trump wins

Pfizer shares new details on obesity pipeline, hints at ‘other opportunities’

GSK buys autoimmune T cell engager for $300M upfront from Chimagen

Novartis takes $800M MorphoSys writedown mere months after closing acquisition

Novartis highlights overall M&A track record following MorphoSys impairment

Following March inspection, Novo Nordisk's semaglutide manufacturing facility cited by FDA

Aim­mune's PhI­II peanut al­ler­gy study wows on the pri­ma­ry end­point, set­ting up FDA pitch -- and shares slide

Editor & Founder

Sign up to read this article for free.

more like this

Viridian Therapeutics

Waltham, MA, USA

Aimmune's PhIII peanut allergy study wows on the primary endpoint, setting up FDA pitch -- and shares slide